Artiva Biotherapeutics Files 8-K on Officer/Director Changes
Ticker: ARTV · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1817241
| Field | Detail |
|---|---|
| Company | Artiva Biotherapeutics, Inc. (ARTV) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40,000, $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance, filing
Related Tickers: ARVA
TL;DR
Artiva Biotherapeutics (ARVA) filed an 8-K detailing leadership changes and financial updates.
AI Summary
Artiva Biotherapeutics, Inc. filed an 8-K on October 22, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits. The report date is October 21, 2024.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors or officers can signal internal shifts that may affect the company's future performance and strategy.
Key Numbers
- 001-42179 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-3614316 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Artiva Biotherapeutics, Inc. (company) — Registrant
- October 21, 2024 (date) — Earliest event reported
- October 22, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers'.
What is the date of the earliest event reported in this 8-K?
The earliest event reported is dated October 21, 2024.
What is the company's principal executive office address?
The principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, California 92121.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code is 2836 for Biological Products (No Diagnostic Substances).
What other items are included in this filing besides officer and director information?
The filing also includes 'Financial Statements and Exhibits'.
Filing Stats: 879 words · 4 min read · ~3 pages · Grade level 10.5 · Accepted 2024-10-22 16:13:52
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ARTV Nasdaq Glo
- $40,000 — will receive an annual cash retainer of $40,000 for service on the Board and (ii) was g
- $15,000 — will receive an annual cash retainer of $15,000 for service as a member of the Technica
Filing Documents
- d855080d8k.htm (8-K) — 27KB
- 0001193125-24-241059.txt ( ) — 151KB
- artv-20241021.xsd (EX-101.SCH) — 3KB
- artv-20241021_lab.xml (EX-101.LAB) — 18KB
- artv-20241021_pre.xml (EX-101.PRE) — 11KB
- d855080d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2024 ARTIVA BIOTHERAPEUTICS, INC. By: /s/ Fred Aslan, M.D. Fred Aslan, M.D. President and Chief Executive Officer